Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
inhalation
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:available_on |
generic version
|
| gptkbp:brand |
gptkb:Symbicort
|
| gptkbp:class |
gptkb:Android
long-acting beta agonist |
| gptkbp:clinical_trial |
ongoing studies
completed studies relief of bronchospasm maintenance treatment |
| gptkbp:clinical_use |
preventive treatment
long-term management |
| gptkbp:contains |
gptkb:budesonide
gptkb:formoterol |
| gptkbp:contraindication |
hypersensitivity to components
severe asthma attacks |
| gptkbp:dosage_form |
twice daily
metered-dose inhaler turbuhaler |
| gptkbp:drug_interactions |
MAO inhibitors
diuretics beta-blockers |
| gptkbp:financial_support |
available resources
|
| gptkbp:form |
aerosol
|
| https://www.w3.org/2000/01/rdf-schema#label |
Symbicort
|
| gptkbp:invention |
patented
|
| gptkbp:is_effective_against |
improves lung function
reduces asthma attacks reduces COPD exacerbations |
| gptkbp:manufacturer |
gptkb:Astra_Zeneca
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:patient_population |
consult healthcare provider
read patient leaflet |
| gptkbp:price |
varies by location
|
| gptkbp:requires |
available online
|
| gptkbp:research |
published in medical journals
|
| gptkbp:route_of_administration |
inhalation
|
| gptkbp:safety_features |
generally well tolerated
monitor for side effects |
| gptkbp:side_effect |
dizziness
headache nausea cough throat irritation |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:type_of_care |
important for effectiveness
|
| gptkbp:type_of_insurance |
may be covered
|
| gptkbp:used_for |
gptkb:asthma
chronic obstructive pulmonary disease |
| gptkbp:bfsParent |
gptkb:Astra_Zeneca
|
| gptkbp:bfsLayer |
4
|